Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07693205

A Prospective, Randomized, Subject- and Examiner-Masked, Multicenter Study Comparing Bilateral Clareon TruPlus and Bilateral Clareon Monofocal Intraocular Lens Implantation (Spherical and Toric) in Cataract Subjects

This investigator-initiated trial is a prospective, randomized, parallel-group, bilateral implantation study comparing Clareon TruPlus versus Clareon monofocal intraocular lenses (IOLs). Spherical and toric models are permitted in both arms based on standardized preoperative planning and clinical indication. Subjects and postoperative examiners/technicians will be masked to IOL assignment; surgeons will not be masked. The overall structure is modeled after randomized bilateral implantation cataract study designs with a Month 3 primary endpoint visit.

Recruiting

Interested in participating?

Request Info

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Berkeley Eye Center - Sugar Land

Sugar Land, Texas, 77478, United States

Location status: Recruiting

Location contact

Tetiana Clinical Research Coordinator

CONTACT

[email protected]

713-526-1600

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult cataract patients aged ≥22 years scheduled for cataract surgery in both eyes due to visually significant cataracts.
  • Ability to understand and sign an IRB/ethics committee-approved informed consent form.
  • Willingness and ability to attend all scheduled study visits as required by the protocol and complete all study testing procedures.
  • Postoperative potential visual acuity of 20/25 or better in each eye, as determined by the investigator.
  • Preoperative corneal astigmatism that can be corrected with a T3-T5 toric IOL, or with a spherical IOL plus LRIs/Aks, with either resulting in a predicted postoperative astigmatism <0.50 D.
  • IOL power and, if toric, cylinder availability within labeled ranges for the assigned IOL family.
  • Ability to understand and complete study questionnaires.

Exclusion criteria

  • Women who are pregnant, planning to become pregnant during the study period, or breastfeeding (by verbal confirmation).
  • Ocular conditions that could confound study results, including moderate-to-severe corneal pathology, irregular astigmatism, moderate-to-severe dry eye/ocular surface disease not optimized, preexisting retinal degenerative disease (e.g., age-related macular degeneration), diabetic retinopathy, or other clinically significant retinal pathology.
  • Any form of confirmed glaucomatous optic neuropathy or other optic nerve disease expected to affect visual function outcomes.
  • History of amblyopia, monofixation syndrome, or other binocular vision disorder with poor stereopsis that could confound binocular testing.
  • Prior ocular surgery (including corneal refractive surgery) in either eye.
  • Zonular laxity/dehiscence, pseudoexfoliation with clinically significant zonulopathy, nystagmus, or strabismus that could compromise uncomplicated surgery or reliable visual testing.
  • Participation in another clinical study (interventional) that could interfere with study results.
  • Planned monovision/mini-monovision or desire for monovision targeting.
  • Systemic conditions that may affect healing or visual outcomes (e.g., uncontrolled diabetes mellitus, certain autoimmune disorders) per investigator judgment.
  • Psychiatric or cognitive disorders that may impair the ability to comply with study procedures or provide reliable self-assessments.
  • Any active ocular infection or inflammation.

Treatment and study plan

Clareon TruPlus

Device

Bilateral implantation with Clareon TruPlus

Clareon monofocal

Device

Bilateral implantation with Clareon monofocal

Primary outcomes

  1. Binocular photopic corrected distance visual acuity (CDVA) at 4 m

    Time frame: 3 months postoperatively

Other outcomes

  1. Binocular photopic distance corrected intermediate visual acuity (DCIVA) at 66 cm

    Time frame: 3 months postoperatively

  2. Binocular photopic distance corrected near visual acuity (DCNVA) at 40 cm

    Time frame: 3 months postoperatively

  3. Binocular mesopic corrected distance visual acuity (CDVA) at 4 m

    Time frame: 3 months postoperatively

  4. Binocular photopic uncorrected distance visual acuity (UDVA) at 4 m

    Time frame: 3 months postoperatively

  5. Binocular photopic uncorrected intermediate visual acuity (UIVA) at 66 cm

    Time frame: 3 months postoperatively

  6. Binocular photopic uncorrected near visual acuity (UNVA) at 40 cm

    Time frame: 3 months postoperatively

  7. Monocular mesopic corrected distance visual acuity (CDVA) at 4 m

    Time frame: 3 months postoperatively

  8. Monocular mesopic distance corrected intermediate visual acuity (DCIVA) at 66 cm

    Time frame: 3 months postoperatively

  9. Binocular mesopic best corrected distance contrast sensitivity without glare

    Time frame: 3 months postoperatively

  10. Binocular mesopic best corrected distance contrast sensitivity with glare

    Time frame: 3 months postoperatively

  11. Photopic low-contrast (25%) BCDVA at 4 m without glare

    Time frame: 3 months postoperatively

  12. Binocular photopic distance-corrected defocus curve

    Time frame: 3 months postoperatively

  13. Monocular distance-corrected defocus curve (dominant eye)

    Time frame: 3 months postoperatively

  14. Visual disturbances questionnaire

    Time frame: 3 months postoperatively

    Questionnaire for Visual Disturbances (QUVID). Lower scores indicate less frequent, severe, or bothersome visual disturbances.

  15. Satisfaction questionnaire

    Time frame: 3 months postoperatively

    The Intraocular Lens Satisfaction questionnaire (IOLSAT). Lower scores indicate higher spectacle independence and satisfaction.

Study contacts

Contact information is provided by the study sponsor or research team.

Tetiana Huff

CONTACT

[email protected]

713-620-7640

Sponsors and collaborators

Lead sponsor

Berkeley Eye Center

Other

Collaborators

  • Sengi

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 9, 2026
Registry last updated
Jul 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.